Foghorn Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Net Income	-98.43	-108.88	-101.32	-68.8	-51.13	Upgrade
Depreciation & Amortization	8.66	7.9	7.52	5.53	1.79	Upgrade
Share-Based Compensation	16.19	14.34	8.38	2.96	1.69	Upgrade
Other Operating Activities	-44.53	280.26	35.17	29.03	1.31	Upgrade
Operating Cash Flow	-118.11	193.61	-50.25	-31.29	-46.34	Upgrade
Capital Expenditures	-1.22	-1.21	-3.31	-15.93	-0.96	Upgrade
Change in Investments	145.67	-243.11	39.49	-92.98	0	Upgrade
Investing Cash Flow	144.45	-244.32	36.17	-108.91	-0.96	Upgrade
Share Issuance / Repurchase	1.78	1.76	43.62	123.34	0.69	Upgrade
Debt Issued / Paid	0	0	-21.21	4.27	7.98	Upgrade
Other Financing Activities	-	-	-	89.86	15.29	Upgrade
Financing Cash Flow	1.78	1.76	22.42	217.47	23.97	Upgrade
Net Cash Flow	28.12	-48.95	8.34	77.27	-23.33	Upgrade
Free Cash Flow	-119.33	192.4	-53.56	-47.22	-47.3	Upgrade
Free Cash Flow Margin	-349.38%	1000.63%	-4060.88%	-10981.16%	-	Upgrade
Free Cash Flow Per Share	-2.84	4.63	-1.44	-4.27	-11.28	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).